Cytokinetics to present at major June healthcare investor conferences

Cytokinetics announced that its management team will participate in two key investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 8. These events will include fireside chats accessible via live webcast on the company's website. Cytokinetics is advancing its cardiovascular drug pipeline, including the approved MYQORZO for obstructive hypertrophic cardiomyopathy and investigational drugs like omecamtiv mecarbil and ulacamten. The company plans to present full Phase 3 trial results for aficamten soon and engage with regulatory authorities, highlighting its ongoing development efforts in cardiac muscle disease treatments.